|
|
|
40
|
50831
|
NEBIDO 250MG/ML INJ (BSP/COL) TESTOSTERONE
|
TESTOSTERONE
|
NEBIDO
|
4ML VIAL
|
BQ
|
108.73
|
108.73
|
INJECTION
|
0
|
VIAL
|
BSP
|
BAYER SCHERING PHARMA AG.
|
COL
|
COLLINS LTD
|
|
6808
|
ANDROGENS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
HORMONES AND SYNTHETIC SUBSTITUTES
|
|
|
|
|
40
|
50833
|
NEBIDO 250MG/ML INJ (BSP/AHI) TESTOSTERONE
|
TESTOSTERONE
|
NEBIDO
|
4ML VIAL
|
BQ
|
108.73
|
108.73
|
INJECTION
|
0
|
VIAL
|
BSP
|
BAYER SCHERING PHARMA AG.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
6808
|
ANDROGENS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
HORMONES AND SYNTHETIC SUBSTITUTES
|
|
|
|
|
42
|
50837
|
PRIMOTESTON 250MG/ML INJ (BSP) TESTOSTER
|
TESTOSTERONE
|
PRIMOTESTON
|
250MG AMP
|
BQ
|
33.14
|
33.14
|
AMPG
|
4
|
AMP
|
BSP
|
BAYER SCHERING PHARMA AG.
|
COL
|
AVENTA BARBADOS
|
|
6808
|
ANDROGENS
|
2026-04-01
|
|
|
IV
|
0
|
ANDROGENS
|
|
|
|
|
42
|
50838
|
PRIMOTESTON 250MG/ML INJ (BSP) TESTOSTER
|
TESTOSTERONE
|
PRIMOTESTON
|
250MG AMP
|
BQ
|
36.43
|
36.43
|
AMPG
|
4
|
AMP
|
BSP
|
BAYER SCHERING PHARMA AG.
|
AHI
|
ARMSTRONG HEALTHCARE INC
|
|
6808
|
ANDROGENS
|
2026-04-01
|
|
|
IV
|
0
|
ANDROGENS
|
|
|
|
|
40
|
5083C
|
TESTOSTERONE 250MG/ML INJ (RTM/PHA)
|
TESTOSTERONE
|
TESTOSTERONE
|
10X1ML
|
BQ
|
140.81
|
14.08
|
INJECTION
|
0
|
AMP
|
RTM
|
PANPHARMA GMBH
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
6808
|
ANDROGENS
|
2022-04-01
|
2024-03-31
|
|
IV
|
0
|
HORMONES AND SYNTHETIC SUBSTITUTES
|
|
|
|
|
41
|
5083C
|
TESTOSTERONE 250MG/ML INJ (RTM) (BQ)
|
TESTOSTERONE
|
TESTOSTERONE
|
10X1ML
|
BQ
|
157.34
|
15.7337
|
AMP
|
4
|
BOX
|
RTM
|
PANPHARMA GMBH
|
PHA
|
PHARMACY SALES CARIBBEAN
|
|
6808
|
ANDROGENS
|
2024-04-01
|
2026-03-31
|
|
IV
|
6
|
ANDROGENS
|
|
|
|
|
41
|
5083D
|
SOSTENON 250MG/ML INJ (ASG) TESTOSTERONE (BQ)
|
TESTOSTERONE
|
SOSTENON
|
250MG PFS
|
BQ
|
34.17
|
34.1693
|
PFS
|
4
|
BOX
|
ASG
|
ASPEN OSD (GLOBAL)
|
STO
|
BRYDEN STOKES LTD
|
|
6808
|
ANDROGENS
|
2024-04-01
|
2026-03-31
|
|
IM
|
6
|
ANDROGENS
|
|